诚达药业：10月24日召开董事会会议

Group 1 - The core point of the article is that Chengda Pharmaceutical (SZ 301201) held its 14th meeting of the 5th Board of Directors on October 24, 2025, where it reviewed the proposal to amend the "Audit Committee Annual Work Regulations" [1] - For the year 2024, Chengda Pharmaceutical's revenue composition is as follows: 55.67% from pharmaceutical manufacturing, 43.0% from food manufacturing, 0.69% from other businesses, and 0.65% from trade-related income [1] - As of the time of reporting, Chengda Pharmaceutical has a market capitalization of 5.1 billion yuan [1]